@Biotech2k1 This article beyond my analytics, but believe more studies like this has to happen to better understand best source and method of expansion of NK cells $FATE $SANA $IPSC $GMDA $CRBU https://t.co/WaspwUzpgT
DYOR - open ?s with NK Cell therapies $FATE $GMDA $IPSC $CELU -- Durability and need for lymphodepleting chemo is closing with RCT underway. Wide open is source of NK cells -- UBC, HSC/ progenitor cells, peripheral blood, or iPSCs? https://t.co/WaspwUR0
@BrianUherek Here is prescient quote from Dr. Miller in this 2020 review “ the best NK-cell source remains to be determined” ie cord blood vs cord blood hematopoietic stem/progenitor cells vs iPSC. Implications for $FATE $GMDA $AFMD see this article ht
@brendan_49 Intuitively agree that auto for NK seems like a wasted effort compared to other routes. UCSD iPSC NK pioneer seems to have second thoughts about cb vs iPsc derived NK. Thoughts on linked paper? https://t.co/Jv0iWSu77n